Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spotlight Innovation has selected ImmunoClin to act as its contract research organization (CRO) for its subsidiary Celtic Biotech Iowa's Part II of its Phase I clinical trial, Crotoxin to treat patients with advanced cancer using an intravenous route of administration.
Subscribe to our email newsletter
ImmunoClin will be responsible for managing and coordinating all aspects of the clinical trial on behalf of Celtic including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation president and CEO Cris Grunewald said: We are pleased to be moving forward with Celtic Biotech’s clinical trial schedule, and to be partnering with a CRO service leader like ImmunoClin.
"We continue to build value in Celtic Biotech, and to move toward the realization of a product portfolio that will have a positive impact on the health and well-being of as many people as possible."
Celtic Biotech president Dr Paul Reid said: "ImmunoClin’s team has formidable experience in the oncology field and they offer unparalleled clinical development expertise. We look forward to working with them."
Celtic Biotech is focused on developing new, clinical trial-phase products to treat cancers and pain in humans.
The new products, derived from naturally specialized receptor-binding proteins, will have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.